T1	CHEM 1144 1147	ARA
#1	AnnotatorNotes T1	C0815017; Angiotensin Receptor Antagonists; Pharmacologic Substance
T2	ANAT 82 86	SRAA
#2	AnnotatorNotes T2	C0086907; Renin-Angiotensin-Aldosterone System; Body System
T3	DISO 105 111	obesos
#3	AnnotatorNotes T3	C0028754; Obesity; Disease or Syndrome
T4	DISO 174 182	obesidad
#4	AnnotatorNotes T4	C0028754; Obesity; Disease or Syndrome
T5	DISO 204 215	proteinuria
#5	AnnotatorNotes T5	C0033687; Proteinuria; Finding
T6	DISO 218 245	insuficiencia renal crónica
#6	AnnotatorNotes T6	C0403447; Chronic Kidney Insufficiency; Disease or Syndrome | C1561643; Chronic Kidney Diseases; Disease or Syndrome
T7	DISO 274 294	enfermedades renales
#7	AnnotatorNotes T7	C0022658; Kidney Diseases; Disease or Syndrome
T8	DISO 313 319	obesos
#8	AnnotatorNotes T8	C0028754; Obesity; Disease or Syndrome
T9	ANAT 358 397	sistema renina-angiotensina-aldosterona
#9	AnnotatorNotes T9	C0086907; Renin-Angiotensin-Aldosterone System; Body System
T10	ANAT 399 403	SRAA
#10	AnnotatorNotes T10	C0086907; Renin-Angiotensin-Aldosterone System; Body System
T11	CHEM 425 436	aldosterona
#11	AnnotatorNotes T11	C0002006; aldosterone; Organic Chemical · Pharmacologic Substance · Hormone
T12	CHEM 551 607	inhibidores de la enzima convertidora de la angiotensina
#12	AnnotatorNotes T12	C0003015; Angiotensin-Converting Enzyme Inhibitors; Pharmacologic Substance
T13	CHEM 609 613	IECA
#13	AnnotatorNotes T13	C0003015; Angiotensin-Converting Enzyme Inhibitors; Pharmacologic Substance
T14	PROC 456 477	comparado la eficacia
#14	AnnotatorNotes T14	C1707887; Efficacy Study; Research Activity
T15	CHEM 673 703	antagonistas de la aldosterona
#15	AnnotatorNotes T15	C0002007; Aldosterone Antagonists; Pharmacologic Substance
T16	DISO 718 724	obesos
#16	AnnotatorNotes T16	C0028754; Obesity; Disease or Syndrome
T17	DISO 729 754	nefropatías proteinúricas
T18	PROC 772 806	estudio prospectivo y aleatorizado
#17	AnnotatorNotes T18	C0033522; Prospective Studies; Research Activity + C0206034; Clinical Trials, Randomized; Research Activity
T19	DISO 874 880	obesos
#18	AnnotatorNotes T19	C0028754; Obesity; Disease or Syndrome
T20	DISO 922 933	proteinuria
#19	AnnotatorNotes T20	C0033687; Proteinuria; Finding
T21	PROC 959 968	consultas
#20	AnnotatorNotes T21	C0009818; Consultation; Health Care Activity
T22	CHEM 1080 1084	IECA
#21	AnnotatorNotes T22	C0003015; Angiotensin-Converting Enzyme Inhibitors; Pharmacologic Substance
T23	CHEM 1086 1096	lisinopril
#22	AnnotatorNotes T23	C0065374; lisinopril; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T24	PROC 1113 1130	terapia combinada
#23	AnnotatorNotes T24	C0013218; Combination Drug Therapy; Therapeutic or Preventive Procedure
T25	CHEM 1135 1139	IECA
#24	AnnotatorNotes T25	C0003015; Angiotensin-Converting Enzyme Inhibitors; Pharmacologic Substance
T26	CHEM 1149 1159	lisinopril
#25	AnnotatorNotes T26	C0065374; lisinopril; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T27	CHEM 1174 1185	candesartán
#26	AnnotatorNotes T27	C0717550; candesartan; Organic Chemical · Pharmacologic Substance
T28	CHEM 1199 1209	eplerenona
#27	AnnotatorNotes T28	C0961485; eplerenone; Organic Chemical · Pharmacologic Substance
T29	PROC 1307 1318	tratamiento
#28	AnnotatorNotes T29	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T30	DISO 1374 1385	proteinuria
#29	AnnotatorNotes T30	C0033687; Proteinuria; Finding
T31	PROC 1422 1433	tratamiento
#30	AnnotatorNotes T31	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T32	PROC 1054 1072	en orden aleatorio
#31	AnnotatorNotes T32	C0034656; Randomization; Research Activity
T33	DISO 1493 1504	proteinuria
#32	AnnotatorNotes T33	C0033687; Proteinuria; Finding
T34	DISO 1582 1593	proteinuria
#33	AnnotatorNotes T34	C0033687; Proteinuria; Finding
T35	CHEM 1607 1617	lisinopril
#34	AnnotatorNotes T35	C0065374; lisinopril; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T36	CHEM 1743 1754	candesartán
#35	AnnotatorNotes T36	C0717550; candesartan; Organic Chemical · Pharmacologic Substance
T37	CHEM 1772 1782	eplerenona
#36	AnnotatorNotes T37	C0961485; eplerenone; Organic Chemical · Pharmacologic Substance
T38	CHEM 1926 1936	lisinopril
#37	AnnotatorNotes T38	C0065374; lisinopril; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T39	DISO 2035 2046	proteinuria
#38	AnnotatorNotes T39	C0033687; Proteinuria; Finding
T40	CHEM 2080 2090	eplerenona
#39	AnnotatorNotes T40	C0961485; eplerenone; Organic Chemical · Pharmacologic Substance
T41	CHEM 2099 2109	lisinopril
#40	AnnotatorNotes T41	C0065374; lisinopril; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T42	CHEM 2112 2123	candesartán
#41	AnnotatorNotes T42	C0717550; candesartan; Organic Chemical · Pharmacologic Substance
T43	CHEM 2138 2148	lisinopril
#42	AnnotatorNotes T43	C0065374; lisinopril; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T44	PROC 2174 2185	monoterapia
#43	AnnotatorNotes T44	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T45	CHEM 2190 2220	antagonistas de la aldosterona
#44	AnnotatorNotes T45	C0002007; Aldosterone Antagonists; Pharmacologic Substance
T46	CHEM 2222 2232	eplerenona
#45	AnnotatorNotes T46	C0961485; eplerenone; Organic Chemical · Pharmacologic Substance
T47	PROC 2239 2261	terapia de combinación
#46	AnnotatorNotes T47	C0013218; Combination Drug Therapy; Therapeutic or Preventive Procedure
T48	CHEM 2266 2270	IECA
#47	AnnotatorNotes T48	C0003015; Angiotensin-Converting Enzyme Inhibitors; Pharmacologic Substance
T49	CHEM 2306 2310	IECA
#48	AnnotatorNotes T49	C0003015; Angiotensin-Converting Enzyme Inhibitors; Pharmacologic Substance
T50	PROC 2314 2325	monoterapia
#49	AnnotatorNotes T50	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T51	DISO 2342 2353	proteinuria
#50	AnnotatorNotes T51	C0033687; Proteinuria; Finding
T52	DISO 2367 2373	obesos
#51	AnnotatorNotes T52	C0028754; Obesity; Disease or Syndrome
T53	DISO 2398 2432	nefropatías crónicas proteinúricas
T54	ANAT 41 80	sistema renina-angiotensina-aldosterona
#52	AnnotatorNotes T54	C0086907; Renin-Angiotensin-Aldosterone System; Body System
T55	CHEM 49 55	renina
#53	AnnotatorNotes T55	C0035094; Renin; Amino Acid, Peptide, or Protein · Enzyme
T56	CHEM 56 68	angiotensina
#54	AnnotatorNotes T56	C0003018; Angiotensins; Amino Acid, Peptide, or Protein · Biologically Active Substance · Pharmacologic Substance
T57	CHEM 69 80	aldosterona
#55	AnnotatorNotes T57	C0002006; aldosterone; Organic Chemical · Pharmacologic Substance · Hormone
T58	ANAT 232 237	renal
#56	AnnotatorNotes T58	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T59	ANAT 287 294	renales
#57	AnnotatorNotes T59	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T60	CHEM 366 372	renina
#58	AnnotatorNotes T60	C0035094; Renin; Amino Acid, Peptide, or Protein · Enzyme
T61	CHEM 373 385	angiotensina
#59	AnnotatorNotes T61	C0003018; Angiotensins; Amino Acid, Peptide, or Protein · Biologically Active Substance · Pharmacologic Substance
T62	CHEM 386 397	aldosterona
#60	AnnotatorNotes T62	C0002006; aldosterone; Organic Chemical · Pharmacologic Substance · Hormone
T63	PROC 414 436	niveles de aldosterona
#61	AnnotatorNotes T63	C0373535; Aldosterone measurement; Laboratory Procedure
T64	CHEM 616 665	antagonistas de los receptores de la angiotensina
#62	AnnotatorNotes T64	C0815017; Angiotensin Receptor Antagonists; Pharmacologic Substance
T65	CHEM 667 670	ARA
#63	AnnotatorNotes T65	C0815017; Angiotensin Receptor Antagonists; Pharmacologic Substance
T66	PROC 882 905	índice de masa corporal
#64	AnnotatorNotes T66	C0005893; Body mass index procedure; Diagnostic Procedure | C3698309; Measurement of body mass index; Health Care Activity
T67	ANAT 897 905	corporal
#65	AnnotatorNotes T67	C0460148; Human body structure; Anatomical Structure | C1318419; Entire human body; Anatomical Structure
T68	PROC 1005 1013	tratados
#66	AnnotatorNotes T68	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T69	CHEM 1730 1740	lisinopril
#67	AnnotatorNotes T69	C0065374; lisinopril; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T70	CHEM 2273 2276	ARA
#68	AnnotatorNotes T70	C0815017; Angiotensin Receptor Antagonists; Pharmacologic Substance
T71	LIVB 95 104	pacientes
#69	AnnotatorNotes T71	C0030705; Patients; Patient or Disabled Group
T72	Spec_cue 194 203	riesgo de
T73	Duration 238 245	crónica
#70	AnnotatorNotes T73	C0205191; chronic; Temporal Concept
T74	LIVB 303 312	pacientes
#71	AnnotatorNotes T74	C0030705; Patients; Patient or Disabled Group
T75	Neg_cue 438 444	Ningún
T76	Date 526 537	actualmente
T77	LIVB 708 717	pacientes
#72	AnnotatorNotes T77	C0030705; Patients; Patient or Disabled Group
T78	LIVB 864 873	pacientes
#73	AnnotatorNotes T78	C0030705; Patients; Patient or Disabled Group
T81	LIVB 988 997	pacientes
#74	AnnotatorNotes T81	C0030705; Patients; Patient or Disabled Group
T82	Duration 1039 1051	seis semanas
T83	Dose 1097 1102	20 mg
T84	Frequency 1102 1106	/día
T85	Dose 1160 1165	10 mg
T86	Frequency 1165 1169	/día
T87	Dose 1186 1191	16 mg
T88	Frequency 1191 1195	/día
T89	Dose 1211 1216	25 mg
T90	Frequency 1216 1220	/día
T91	Duration 1261 1273	seis semanas
T92	Duration 1389 1393	24 h
T93	LIVB 1449 1458	pacientes
#75	AnnotatorNotes T93	C0030705; Patients; Patient or Disabled Group
T96	LIVB 1978 1987	pacientes
#76	AnnotatorNotes T96	C0030705; Patients; Patient or Disabled Group
T98	LIVB 2357 2366	pacientes
#77	AnnotatorNotes T98	C0030705; Patients; Patient or Disabled Group
T99	Duration 2410 2418	crónicas
#78	AnnotatorNotes T99	C0205191; chronic; Temporal Concept
A1	Assertion T5 Speculated
A2	Assertion T6 Speculated
A3	Assertion T14 Negated
T80	Neg_cue 1633 1635	no
T94	Quantifier_or_Qualifier 1640 1670	estadísticamente significativa
#79	AnnotatorNotes T94	C0237881; Statistical Significance; Quantitative Concept
R1	Negation Arg1:T80 Arg2:T94	
R2	Negation Arg1:T75 Arg2:T14	
R3	Speculation Arg1:T72 Arg2:T5	
R4	Speculation Arg1:T72 Arg2:T6	
T79	Observation 1 24	Efecto antiproteinúrico
R5	Experiences Arg1:T71 Arg2:T3	
R6	Experiences Arg1:T71 Arg2:T79	
R7	Overlap Arg1:T79 Arg2:T3	
R8	Before Arg1:T4 Arg2:T5	
R9	Before Arg1:T4 Arg2:T6	
R10	Location_of Arg1:T58 Arg2:T6	
R11	Has_Duration_or_Interval Arg1:T6 Arg2:T73	
R13	Location_of Arg1:T59 Arg2:T7	
T97	Observation 260 294	progresión de enfermedades renales
R14	Before Arg1:T7 Arg2:T97	
R15	Experiences Arg1:T74 Arg2:T8	
R16	Overlap Arg1:T12 Arg2:T76	
R17	Overlap Arg1:T13 Arg2:T76	
R18	Overlap Arg1:T64 Arg2:T76	
R19	Overlap Arg1:T65 Arg2:T76	
R20	Overlap Arg1:T15 Arg2:T76	
R21	Experiences Arg1:T77 Arg2:T16	
R22	Overlap Arg1:T16 Arg2:T17	
R23	Experiences Arg1:T77 Arg2:T17	
R24	Experiences Arg1:T77 Arg2:T12	
R25	Experiences Arg1:T77 Arg2:T13	
R26	Experiences Arg1:T77 Arg2:T64	
R27	Experiences Arg1:T77 Arg2:T65	
R28	Experiences Arg1:T77 Arg2:T15	
T100	Observation 330 337;407 436	aumento de los niveles de aldosterona
#81	AnnotatorNotes T100	C4314076; Elevated aldosterone levels; Finding
T101	PHYS 344 404	actividad del sistema renina-angiotensina-aldosterona (SRAA)
R29	Experiences Arg1:T74 Arg2:T100	
R30	Experiences Arg1:T74 Arg2:T101	
R31	Location_of Arg1:T9 Arg2:T101	
R32	Location_of Arg1:T10 Arg2:T101	
R33	Overlap Arg1:T8 Arg2:T100	
R34	Experiences Arg1:T78 Arg2:T19	
R35	Location_of Arg1:T67 Arg2:T66	
R36	Experiences Arg1:T78 Arg2:T66	
R37	Experiences Arg1:T78 Arg2:T20	
R38	Experiences Arg1:T81 Arg2:T68	
T103	Quantifier_or_Qualifier 1014 1030	consecutivamente
#83	AnnotatorNotes T103	C1707491; Consecutive; Qualitative Concept
R39	Has_Quantifier_or_Qualifier Arg1:T68 Arg2:T103	
R40	Has_Duration_or_Interval Arg1:T68 Arg2:T82	
R41	Used_for Arg1:T22 Arg2:T68	
R42	Used_for Arg1:T23 Arg2:T68	
R43	Experiences Arg1:T81 Arg2:T24	
R44	Combined_with Arg1:T25 Arg2:T1	
R45	Combined_with Arg1:T26 Arg2:T27	
R46	Before Arg1:T32 Arg2:T22	
R47	Before Arg1:T32 Arg2:T23	
R48	Before Arg1:T32 Arg2:T24	
R49	Used_for Arg1:T25 Arg2:T24	
R50	Used_for Arg1:T26 Arg2:T24	
R51	Has_Dose_or_Strength Arg1:T23 Arg2:T83	
R52	Has_Frequency Arg1:T23 Arg2:T84	
R53	Has_Dose_or_Strength Arg1:T26 Arg2:T85	
R54	Has_Frequency Arg1:T26 Arg2:T86	
R55	Has_Dose_or_Strength Arg1:T27 Arg2:T87	
R56	Has_Frequency Arg1:T27 Arg2:T88	
R57	Has_Dose_or_Strength Arg1:T1 Arg2:T87	
R58	Has_Frequency Arg1:T1 Arg2:T88	
R59	Has_Dose_or_Strength Arg1:T25 Arg2:T85	
R60	Has_Frequency Arg1:T25 Arg2:T86	
R61	Has_Frequency Arg1:T28 Arg2:T90	
R62	Has_Dose_or_Strength Arg1:T28 Arg2:T89	
R63	Combined_with Arg1:T69 Arg2:T36	
R64	Before Arg1:T32 Arg2:T28	
R65	Experiences Arg1:T81 Arg2:T28	
T104	CONC 1240 1257	período de lavado
#84	AnnotatorNotes T104	C1710661; Washout Period; Temporal Concept
R66	Has_Duration_or_Interval Arg1:T104 Arg2:T91	
R67	Before Arg1:T29 Arg2:T104	
R68	Overlap Arg1:T30 Arg2:T92	
T105	CONC 1397 1433	final de cada período de tratamiento
T107	CONC 1361 1367	cambio
#86	AnnotatorNotes T107	C0443172; Changed status; Quantitative Concept
R69	Overlap Arg1:T107 Arg2:T105	
R70	Experiences Arg1:T93 Arg2:T30	
R71	Experiences Arg1:T93 Arg2:T33	
T108	CONC 1537 1548	valor basal
#87	AnnotatorNotes T108	C1442488; Baseline; Quantitative Concept
T109	CONC 1566 1575	reducción
#88	AnnotatorNotes T109	C0547047; Decrease; Quantitative Concept
R74	Has_Quantifier_or_Qualifier Arg1:T109 Arg2:T94	
T110	CONC 1687 1698	valor basal
#89	AnnotatorNotes T110	C1442488; Baseline; Quantitative Concept
T111	CONC 1864 1879	valores basales
#90	AnnotatorNotes T111	C1442488; Baseline; Quantitative Concept
R80	Experiences Arg1:T96 Arg2:T39	
R81	Combined_with Arg1:T41 Arg2:T42	
R85	Used_for Arg1:T45 Arg2:T44	
R86	Used_for Arg1:T46 Arg2:T44	
R87	Combined_with Arg1:T48 Arg2:T70	
R88	Used_for Arg1:T48 Arg2:T47	
R89	Used_for Arg1:T49 Arg2:T50	
R90	Experiences Arg1:T98 Arg2:T51	
R91	Overlap Arg1:T52 Arg2:T53	
R92	Experiences Arg1:T98 Arg2:T52	
R93	Experiences Arg1:T98 Arg2:T53	
R94	Has_Duration_or_Interval Arg1:T53 Arg2:T99	
R95	Overlap Arg1:T19 Arg2:T20	
R96	Overlap Arg1:T52 Arg2:T51	
R100	Experiences Arg1:T98 Arg2:T44	
R101	Experiences Arg1:T98 Arg2:T47	
R102	Experiences Arg1:T98 Arg2:T49	
R72	Overlap Arg1:T4 Arg2:T97	
R73	Overlap Arg1:T4 Arg2:T7	
T95	Result_or_Value 906 915	>30 kg/m2
R76	Has_Result_or_Value Arg1:T66 Arg2:T95	
T102	Result_or_Value 934 945	>0,5 g/24 h
R77	Has_Result_or_Value Arg1:T20 Arg2:T102	
R78	Experiences Arg1:T78 Arg2:T21	
R82	Experiences Arg1:T93 Arg2:T31	
#80	AnnotatorNotes T76	C0521116; Current (present time); Temporal Concept
#82	AnnotatorNotes T17	C5677904; Proteinuric nephropathy; Finding
A4	Experiencer T71 Patient
A5	Experiencer T74 Patient
A6	Experiencer T77 Patient
A7	Experiencer T78 Patient
A8	Experiencer T81 Patient
A9	Experiencer T93 Patient
A10	Experiencer T96 Patient
A11	Experiencer T98 Patient
